

Driving **real world patient impact** and **healthcare productivity** gains in line with the **NHS Ten-Year Plan** goals, today.

Enabling a shift from “sickness” to “**Prevention**”

- » Our CYP2C19 near-patient genetic test enables clinical targeting of optimal antiplatelet therapies, reducing the risk of secondary stroke recurrence.
- » Our MT-RNR1 near-patient genetic test enables reduction of risk of lifelong, profound and irreversible deafness in neonates exposed to aminoglycoside antibiotics.

Our products offer

£160m

of value to NHS each year (**£1.6Bn over the 10 year plan**)

Our technology is already delivering improved patient outcomes in real-world NHS environments.

Scaling nationally would save hundreds of millions across the NHS.

In Greater Manchester, our CYP2C19 ID Kit test is already being used in the UK's largest stroke unit, Salford's Hyper Acute Stroke Unit.

£8.79^{*}
Million annual savings



*Full adoption could deliver in the Greater Manchester area alone.

Our MT-RNR1 ID Kit test is being piloted in neonatal intensive care units being used in 14 NICUs in England and Wales, and is being rolled out nationally in Scotland.

£6m^{**}
Million annual savings

** This cost-effective test could save the NHS £6 million a year in lifetime support and services by reducing the need for bilateral cochlear implants, thereby reducing appointments and check-ups and driving down waiting lists.

Stroke Prevention - Personal antiplatelet treatments

- » **100,000 strokes** occur each year. 50% of stroke survivors are dependent on others for everyday tasks
- » **Stroke patients** take up more than **1 million hospital bed days** annually.
- » Despite recurrent strokes being considered highly preventable, the healthcare burden remains significant.
- » On average, patients with recurrent stroke spend **8.4 more days in hospital** than patients having their first stroke.
- » Clopidogrel is the first-line treatment for secondary prevention of stroke, but at least **25% of the UK population is resistant to clopidogrel**.
- » **Genedrive's NICE-recommended** near-patient genetic test enables determination of a **patients CYP2C19 genotype** and aids clinical decision making in stroke management.
- » **Reduce risk** of recurrent stroke.
- » Release **62,505 hospital beds** annually and reduce bed blocking.

- » **Free up 230,699 clinical hours** annually, which could be redirected to treat other patients on hospital and GP waiting lists.
- » Offer 160m of value annually to the NHS. **1.6Bn over the course of the 10 year plan.**
- » Our **rapid genetic testing** potentially **prevents c.3000 recurrent strokes** annually.



Following a stroke, patients have a significantly higher risk of a repeated event within the first 48 hours.

This is why it is important to initiate the best treatment for secondary prevention as soon as possible.

£160m *
million of value annually to the NHS

£ £ £ £ £ £ £ £ £ £

*1.6Bn over the course of the 10 year plan.



1 in 7 babies born are admitted into the NICU.

Antibiotic Induced Hearing Lost (AIHL) – Personalised antibiotic treatment

- » **Approximately 1 in 500 individuals** carry a gene variant that puts them at **high risk of profound, bilateral and irreversible hearing loss**, requiring cochlear implants if they are administered aminoglycoside antibiotics.
- » **90,000 babies** are admitted to UK NICUs each year, with a high percentage suspected of having sepsis, requiring **administration of aminoglycoside antibiotics within 1 hour** of decision to treat.
- » **Genedrive's test is a world first**, and the only test available to determine **MT-RNR1 genotype status** which can be used to **reduce risk** of lifelong deafness caused by aminoglycoside exposure in c. 200 at-risk neonates each year in the UK.
- » **Provides rapid genetic test results** in NICU settings, within **the golden hour** required.



They need to be treated within 1 hour of diagnosis.



For more information, contact us at enquiries@genedrive.com

Intellectual Property

*References available on request. Genedrive® is a registered trademark of Genedrive Diagnostics Ltd. Copyright © 2025 genedrive plc. All rights reserved. GPM-185 V2 October 2025

genedrive